"The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.
Kcentra, (Prothrombin Complex Concentrate (Human)), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding.
Kcentra is not indicated for urgent reversal of VKA anticoagulation in patients without acute major bleeding.
DOSAGE AND ADMINISTRATION
For intravenous use only.
- The actual potency per vial of Factors II, VII, IX and X, Proteins C and S is stated on the carton.
- Individualize Kcentra dosing based on the patient's current pre-dose International Normalized Ratio (INR) value, and body weight.
- Administer Vitamin K concurrently to patients receiving Kcentra. Vitamin K is administered to maintain Vitamin K-dependent clotting factor levels once the effects of Kcentra have diminished.
- Repeat dosing with Kcentra is not supported by clinical data and is not recommended.
- Dose ranging other than what is recommended has not been studied in randomized clinical trials of Kcentra.
Dosage Required for Reversal of VKA Anticoagulation in Patients with Acute Major Bleeding
Reconstitute Kcentra with 20 mL of diluent (Sterile Water for Injection, USP) provided with the kit. When reconstituted, the final concentration of drug product in Factor IX units will be in a range from 20-31 units/mL, depending on the actual potency, which is listed on the carton.
Coagulation factor levels may be unstable in patients with acute major bleeding who are receiving Vitamin K. Measure INR prior to treatment close to the time of dosing, then individualize dosage based on the INR value and the subject's body weight (kg) as shown in Table 1 below.
Table 1: Dosing Guideline
|Pre-treatment INR||2 - < 4||4 - 6||> 6|
|Dose* of Kcentra (units† of Factor IX) / kg body weight||25||35||50|
|Maximum dose‡ (units of Factor IX)||Not to exceed 2500||Not to exceed 3500||Not to exceed 5000|
|* Dosing is based on body weight. Dose based on actual
potency as stated on the carton, which will vary from 20-31 Factor IX units/mL.
Nominal potency is 500 units per vial, approximately 25 units per mL after
† Units refer to International Units.
‡ Dose is based on body weight up to but not exceeding 100 kg. For patients weighing more than 100 kg, maximum dose should not be exceeded.
Example dosing calculation for 80 kg patient
For example, an 80 kg patient with a baseline of INR of 5.0, the dose would be 2,800 Factor IX units of Kcentra, calculated as follows based on INR range of 4-6, see Table 1:
35 units of Factor IX/kg x 80 kg = 2,800 units of Factor IX required*
* For a vial with an actual potency of 30 units/mL Factor IX, 93 mL would be given (2,800 U/30 U per mL = 93 mL)
Monitor INR and clinical response during and after treatment. In clinical trials, Kcentra decreased the INR to ≤ 1.3 within 30 minutes in most subjects. The relationship between this or other INR values and clinical hemostasis in patients has not been established [see Clinical Studies]
Preparation and Reconstitution
- Reconstitute using aseptic technique with 20 mL of diluent provided with the kit.
- Do not use Kcentra beyond the expiration date on the vial label and carton.
- Visually inspect parenteral drug products for particulate matter and discoloration prior to administration whenever solution and container permit. Reconstituted Kcentra solution should be colorless, clear to slightly opalescent, and free from visible particles. Do not use solutions that are cloudy or have deposits.
- Kcentra is for single use only. Contains no preservatives. Discard partially used vials.
The procedures provided in Table 2 are general guidelines for the preparation and reconstitution of Kcentra.
Reconstitute at room temperature as follows:
Table 2: Kcentra Reconstitution Instructions
1. Ensure that the Kcentra vial and diluent vial are at room temperature. Prepare and administer using aseptic technique.
2. Place the Kcentra vial, diluent vial, and Mix2Vial® transfer set on a flat surface.
3. Remove Kcentra and diluent vial flip caps. Wipe the stoppers with the alcohol swab provided and allow to dry prior to opening the Mix2Vial transfer set package.
4. Open the Mix2Vial transfer set package by peeling away the lid. [Fig. 1] Leave the Mix2Vial transfer set in the clear package.
5. Place the diluent vial on a flat surface and hold the vial tightly. Grip the Mix2Vial transfer set together with the clear package and push the plastic spike at the blue end of the Mix2Vial transfer set firmly through the center of the stopper of the diluent vial. [Fig. 2]
6. Carefully remove the clear package from the Mix2Vial transfer set. Make sure that you pull up only the clear package, not the Mix2Vial transfer set. [Fig. 3]
7. With the Kcentra vial placed firmly on a flat surface, invert the diluent vial with the Mix2Vial transfer set attached and push the plastic spike of the transparent adapter firmly through the center of the stopper of the Kcentra vial. [Fig. 4] The diluent will automatically transfer into the Kcentra vial.
8. With the diluent and Kcentra vial still attached to the Mix2Vial transfer set, gently swirl the Kcentra vial to ensure that the Kcentra is fully dissolved. [Fig. 5] Do not shake the vial.
9. With one hand, grasp the Kcentra side of the Mix2Vial transfer set and with the other hand grasp the blue diluent-side of the Mix2Vial transfer set, and unscrew the set into two pieces. [Fig. 6]
10. Draw air into an empty, sterile syringe. While the Kcentra vial is upright, screw the syringe to the Mix2Vial transfer set. Inject air into the Kcentra vial. While keeping the syringe plunger pressed, invert the system upside down and draw the concentrate into the syringe by pulling the plunger back slowly. [Fig. 7]
11. Now that the concentrate has been transferred into the syringe, firmly grasp the barrel of the syringe (keeping the plunger facing down) and unscrew the syringe from the Mix2Vial transfer set. [Fig. 8] Attach the syringe to a suitable intravenous administration set.
12. After reconstitution, administration should begin promptly or within 4 hours.
13. If the same patient is to receive more than one vial, you may pool the contents of multiple vials. Use a separate unused Mix2Vial transfer set for each product vial.
- Do not mix Kcentra with other medicinal products; administer through a separate infusion line.
- Use aseptic technique when administering Kcentra.
- Administer at room temperature.
- Administer by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
- No blood should enter the syringe, as there is a possibility of fibrin clot formation.
- Record the lot number of the product in the patient's medical record when Kcentra is administered to the patient.
Dosage Forms And Strengths
- Kcentra is available as a single use vial containing coagulation Factors II, VII, IX and X, antithrombotic Proteins C and S as a lyophilized concentrate.
- Kcentra potency (units) is defined by Factor IX content. The range of Factor IX units per vial is 400-620 units. When reconstituted using 20 mL of diluent, the final concentration of drug product in Factor IX units will be in a range from 20-31 units/mL.
- The actual content of Factor IX as measured in units of potency is stated on the vial.
- The actual units of potency for each coagulation factor (Factors II, VII, IX and X), and Proteins C and S are stated on the carton.
- Kcentra is supplied in a single-use vial.
- The actual units of potency of all coagulation factors (Factors II, VII, IX and X), Proteins C and S in units are stated on each Kcentra carton.
- The Kcentra packaging components are not made with natural rubber latex.
Each kit consists of the following:
Storage and Handling
Prior to Reconstitution
- Kcentra is for single use only. Contains no preservatives.
- Store Kcentra between 2 - 25°C (36 - 77°F), this includes room temperature, not to exceed 25°C (77°F). Do not freeze.
- Kcentra is stable for 36 months from the date of manufacture, up to the expiration date on the carton and vial labels.
- Do not use beyond the expiration date on the carton and the vial label.
- Store the vial in the original carton to protect it from light.
- The product must be used within 4 hours following reconstitution. Reconstituted product can be stored at 2 - 25°C. If cooled, the solution should be warmed to 20 - 25°C prior to administration. Do not freeze the reconstituted product. Discard partially used vials.
Manufactured by: CSL Behring GmbH, 35041 Marburg Germany. Distributed by: CSL Behring LLC, Kankakee, IL 60901 USA. Revised: April 2013This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 8/12/2013
Additional Kcentra Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.